Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

The Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...

NOVO Nordisk on Wednesday announced that Wegovy (semaglutide injection) is now approved to reduce the risk of non-fatal ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

(Bloomberg) -- Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and Wegovy, the ...

A dose of four Wegovy injections will cost 1,400 yuan ($194), a fraction of the drug’s U.S. price, according to the Chinese ...

Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...